BingX Launches $150M Shield Fund to Set a New Benchmark for User Protection
PANAMA CITY, June 5, 2025 /CNW/ -- BingX, a leading global cryptocurrency exchange and Web3 AI company, has introduced the Shield Fund, a permanent $150 million safety reserve dedicated to safeguarding users against unforeseen cyber threats and extreme market volatility. Unlike conventional insurance models, the Shield Fund is entirely self-funded and always active, enabling BingX to respond swiftly during crises. This initiative underscores BingX's commitment to transparency, accountability, and its unwavering user-first vision.
Built with long-term sustainability in mind, the Shield Fund features continuous internal audits and dynamic risk assessments to adapt to evolving market conditions. It offers BingX users an added layer of real-time protection and peace of mind, solidifying BingX's position as a leader in secure and responsible crypto trading.
"The launch of the BingX Shield Fund is a strategic extension of our user-first vision. It is not simply a financial safeguard — it is a symbol of how we view responsibility at scale," said Vivien Lin, Chief Product Officer at BingX. "We are reaffirming our commitment to building a secure, transparent, and forward-thinking trading environment. As our platform grows, so does our duty to empower users with tools and systems that ensure confidence, resilience, and long-term trust."
Following the implementation of Proof-of-Reserve, the Shield Fund represents the next chapter in BingX's ongoing mission to elevate platform integrity and user protection. Together, these initiatives form a robust foundation for a more transparent, secure, and accountable trading environment. Looking ahead, BingX remains committed to delivering proactive safety measures and pioneering infrastructure innovations to safeguard user interests.
Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
CSA proposes amendments to modernize and streamline mining disclosure standards Français
VANCOUVER, BC, June 12, 2025 /CNW/ - The Canadian Securities Administrators (CSA) is seeking feedback on proposed amendments to National Instrument 43-101 Standards of Disclosure for Mineral Projects. The proposed amendments are intended to clarify, harmonize and streamline Canada's mining disclosure regime without introducing any new requirements. The proposed amendments would update and enhance the standards for disclosing scientific and technical information about mineral projects to address evolving disclosure practices and policy considerations identified by CSA staff, and to reflect changing industry and investor expectations. "Our goal is to provide investors with clear, reliable information about mineral projects so they can make informed decisions, without imposing an undue regulatory burden on mining issuers," said Stan Magidson, CSA Chair and Chair and CEO of the Alberta Securities Commission. "By modernizing and streamlining the disclosure regime, we aim to maintain Canada's position as the global standard for mining disclosure." The proposed amendments to National Instrument 43-101 Standards of Disclosure for Mineral Projects are designed to: remove or replace certain definitions and requirements that have become outdated modernize and streamline certain requirements to reflect current industry practice provide clarification and guidance on certain definitions and requirements, and make other minor language changes to clarify disclosure requirements. The proposed amendments are being published for a 120-day comment period and are available on CSA member websites. In April 2022, the CSA published CSA Consultation Paper 43-401 Consultation on National Instrument 43-101 Standards of Disclosure for Mineral Projects to inform this project. The CSA received valuable feedback from a large number of market participants, which it has considered. The CSA, the council of the securities regulators of Canada's provinces and territories, coordinates and harmonizes regulation for the Canadian capital markets. For media inquiries, please contact: Ilana Kelemen Canadian Securities Administrators [email protected] Elise Palmer BC Securities Commission [email protected] For investor inquiries, please contact your local securities regulator.
Cision Canada
2 hours ago
- Cision Canada
GTA Residents Sound Alarm: Nearly 80% Call Auto Theft a Crisis
2024 auto theft claims data shows slight improvement over 2023, but most GTA residents fear their vehicle will be stolen TORONTO , June 12, 2025 /CNW/ - New data from Insurance Bureau of Canada (IBC) confirms Ontario remains in the midst of an auto theft crisis, with the number of insurance claims up 165% since 2017 and the costs to service those claims up a staggering 538%. Even more troubling is how residents of the Greater Toronto Area (GTA) – where the vast majority of vehicles are stolen – view the auto theft crisis. According to a new Pollara Strategic Insights poll commissioned by IBC, 63% of GTA residents live in fear of their vehicle being stolen and more than half (56%) reporting that the crisis is affecting their community. Continue Reading Auto Theft Claims in Ontario (CNW Group/Insurance Bureau of Canada) "We still have a long way to go to effectively curb auto theft in the province," said Amanda Dean , Vice-President, Ontario and Atlantic, IBC. "The Ontario and federal government's efforts to tackle auto theft are both commendable and were reflected in the decline in claims costs in 2024. But the crisis persists and requires continued leadership and focus." Over the past eight years, auto theft has disrupted thousands of lives and families across Ontario and placed an unprecedented strain on law enforcement, court resources and insurance costs. According to the recent auto theft survey commissioned by IBC, the emotional toll this crisis is having on residents is alarming: 76% believe Ontario is facing an auto theft crisis. is facing an auto theft crisis. 63% of GTA residents are concerned that a vehicle they own, co-own or lease might be stolen in the future. Younger Ontarians express more concern; 75% of those aged 18–34 and 67% of those aged 35–54 are worried about their vehicle being stolen, compared to 52% of those aged 55+. 56% say the crisis is affecting their own community. Auto theft in Ontario Insurance Claims and Costs for Auto Theft, 2017 to 2024 Claims Count Total Cost 2017 7,693 $113,627,636 2018 9,470 $165,474,435 2019 10,426 $211,783,676 2020 10,547 $242,929,120 2021 13,632 $406,390,578 2022 20,497 $760,035,984 2023 25,805 $1,036,937,925 2024 20,418 $724,598,945 IBC analysis based on industry data from GISA systems. " Ontario's insurers have taken steps to address the crisis and we look forward to supporting the federal government's recently announced Strong Borders Act as it follows through with its recent commitments to add 1,000 new Canada Border Services Agency officers to manage additional border scanners, drones and new canine teams for Canada's land borders, ports and railyards," added Dean. "Last week's announcement will help to close a gap in the transportation network and prevent stolen vehicles from leaving Canada . We need a whole-of-society approach coordinated through continued federal government leadership and a commitment from all stakeholders to put an end to auto theft." About the Pollara survey Pollara Strategic Insights conducted the online survey from April 23 to April 29, 2025 , among N=1,126 adult (18+) GTA residents. The data set has been weighted by age, gender and region to ensure it accurately represents the demographic and geographic distribution of this population. As a guideline, a probability sample of N=1,126 carries a margin of error of ±2.9% 19 times out of 20. Sub-samples carry higher margins of error. About Insurance Bureau of Canada Established in 1964, Insurance Bureau of Canada (IBC) is the national industry association representing Canada's private home, auto and business insurers. Its member companies make up the vast majority of Canada's highly competitive property and casualty (P&C) insurance market. As the leading advocate for Canada's private P&C insurers, IBC collaborates with governments, regulators and stakeholders to support a competitive environment for the P&C insurance industry to continue to help protect Canadians from the risks of today and tomorrow. IBC believes that Canadians value and deserve a responsive and resilient private P&C insurance industry that provides insurance solutions to both individuals and businesses. For media releases, IN Focus articles, or to book an interview with an IBC representative, visit . Follow us on LinkedIn , X and Instagram, and like us on Facebook . If you have a question about home, auto or business insurance, contact IBC's Consumer Information Centre at 1-844-2ask-IBC. We're here to help. SOURCE Insurance Bureau of Canada Media Contact: Brett Weltman, Manager, Media Relations, IBC, [email protected]
Cision Canada
2 hours ago
- Cision Canada
As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in AI, diagnostics, and even exercise-based interventions, this year's gathering spotlighted a broad array of promising approaches. However, looming over the scientific excitement are concerns about proposed U.S. budget cuts, including a potential 40% reduction in funding for the National Cancer Institute (NCI). As public investment comes under pressure, many are turning to the private sector to carry the load — with recent moves by companies like Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Anixa Biosciences, Inc. (NASDAQ: ANIX), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and ImmunityBio, Inc. (NASDAQ: IBRX). The rising global burden of cancer is driving urgent demand for next-generation therapies. By 2030, annual case counts are expected to climb 20%, with projections pointing to a 75% surge by 2050, according to Statista. Market researchers anticipate oncology spending will scale to match: ResearchAndMarkets forecasts the sector hitting US$866.1 billion by 2034, growing at a 10.8% CAGR, while Vision Research Reports places the market for cancer treatments even higher — surpassing US$903.81 billion at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), just announced a major leadership transition that could mark a pivotal chapter in its clinical and corporate trajectory. The company has appointed Jared Kelly as Chief Executive Officer and member of the Board, a move that brings in a seasoned biotech dealmaker known for high-value M&A and immuno-oncology strategy. Kelly most recently played a central role (as General Counsel) in the $2 billion sale of Ambrx Biopharma to Johnson & Johnson. Prior to that, he advised numerous biotech firms on licensing and acquisitions during his tenure at leading law firms Kirkland & Ellis LLP and Lowenstein Sandler LLP. In joining Oncolytics, he inherits one of the most intriguing immunotherapy agents and pipelines in clinical oncology: pelareorep, a virus-based agent with broad synergy potential in solid and hematologic tumors. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear priority: advancing pelareorep toward late-stage inflection points with a capital-efficient and partnership-aware strategy. The asset currently holds FDA Fast Track designation in both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare distinction that reinforces its regulatory momentum. In trials to date, pelareorep has consistently demonstrated immune activation, synergy with chemotherapies and checkpoint inhibitors, and unusually strong response rates across difficult-to-treat cancers. In metastatic pancreatic cancer (mPDAC), pelareorep has delivered over 60% objective response rates in tumor evaluable patients across Phase 1 and 2 studies—more than double those observed in historical controls — and, separately, two-year survival rates 4-6 times those observed in control patients or in prior studies. In HR+/HER2- metastatic breast cancer, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed meaningful survival benefit. And in anal cancer, early data from a phase 2 cohort combining pelareorep with a checkpoint inhibitor showed partial or complete responses in nearly half of evaluable patients—far exceeding historical norms for monotherapy. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." To align incentives with long-term shareholder value, Kelly's compensation package includes equity and milestone-based awards tied to future strategic transactions and financings. The structure reflects Oncolytics' intention to drive both clinical and corporate progress without overextending its cap table—while remaining attractive to potential collaborators. As multiple programs advance within the GOBLET study—including pancreatic and anal cancer cohorts backed by regulatory support and third-party funding— Oncolytics appears poised to benefit from a combination of scientific traction, capital flexibility, and strategic leadership. In other recent industry developments and happenings in the market include: Anixa Biosciences, Inc. (NASDAQ: ANIX) is advancing two novel programs at the frontlines of cancer immunotherapy. The company will present new data from its first-in-human ovarian cancer CAR-T clinical trial later this month at the ESMO Gynaecological Cancers Congress, showcasing a unique chimeric endocrine receptor T-cell (CER-T) platform targeting the follicle stimulating hormone receptor (FSHR). Separately, Anixa is also working with Cleveland Clinic to develop a preventative breast cancer vaccine designed to train the immune system to recognize "retired" proteins reactivated in early malignancies. "While cancer vaccines have traditionally faced significant hurdles, our approach is aimed at a novel target that has not been previously explored in this context," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We believe this could represent a new paradigm in immuno-oncology. The breast cancer market, particularly for triple-negative breast cancer and genetically high-risk populations, continues to face a major unmet need. Our vaccine may offer a unique, immunologic pathway for both prevention and treatment." Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has published the final five-year analysis from its Phase 2 C-144-01 trial evaluating Amtagvi® (lifileucel), the first FDA -approved T cell therapy for solid tumors in patients with advanced melanoma. "Amtagvi has demonstrated long-term benefit and meaningful overall survival in a difficult-to-treat melanoma patient population resistant to immune checkpoint inhibitor therapy," said Theresa Medina, M.D., medical oncologist at the University of Colorado Cancer Center on the Anschutz Medical Campus. "Five years following one-time Amtagvi treatment, responses persisted or deepened during an extended treatment-free interval for some patients. Amtagvi offers a new standard of care for the advanced melanoma community and sets a new bar for one-time cell therapies with curative intent in solid tumors." The results, featured in the Journal of Clinical Oncology and presented at ASCO 2025, highlight durable responses in heavily pretreated patients—with nearly one-third of responders maintaining benefit five years after a single treatment. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently reported compelling Phase 3 results for Libtayo® (cemiplimab) as an adjuvant therapy in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial showed a 68% reduction in disease recurrence or death and strong secondary endpoint performance, including 80% and 65% reductions in locoregional and distant recurrence, respectively. "The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk CSCC, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence," said Danny Rischin, M.D., Head of Head and Neck Cancer and Cutaneous SCC at Peter MacCallum Cancer Centre. "While surgery and radiotherapy remain the cornerstones of treatment, there is a critical unmet need for systemic therapies to help prevent relapse and metastasis." Regulatory filings have already been submitted in the U.S. and EU, and experts say these findings could reshape treatment standards. ImmunityBio, Inc. (NASDAQ: IBRX) is advancing what may be the first true therapy for lymphopenia—a condition long associated with poor outcomes in cancer but never directly treated until now. "Lymphopenia has long been recognized as a major driver and predictor of early mortality in cancer—yet until now, it has remained unaddressed," said Dr. Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. " Backed by FDA Expanded Access authorization, the company's Cancer BioShield™ platform centers on ANKTIVA®, an IL-15 superagonist approved in bladder cancer and now being deployed to help restore immune function in patients with solid tumors who've exhausted first-line therapies. "This FDA authorization allows all patients with solid tumors suffering from immune collapse following first-line therapy of chemo, radiation, or immunotherapy to access ANKTIVA," said Soon-Shiong. "The survival benefit we observed at ASCO 2025 in 3 rd to 6 th line advanced metastatic pancreatic cancer confirms that restoring lymphocyte levels—rather than depleting them—can change the course of disease." At ASCO 2025, ImmunityBio presented landmark data showing that reversing lymphopenia with ANKTIVA and CAR-NK cells significantly extended survival in late-stage pancreatic cancer patients, especially when intervention occurred at a lower tumor burden. The results represent a potential paradigm shift: treating immune collapse itself—not just the tumor—may drive better long-term outcomes. Based on this mechanism, the platform could open doors to broader applications in oncology, infectious disease, and immune senescence. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
